Surgical resection combined with systemic chemotherapy is the cornerstone of treatment for
patients with localized pancreatic cancer. Upfront surgery is considered suboptimal in cases …

Introduction Neoadjuvant therapy may improve survival compared with upfront surgery in
patients with resectable and borderline resectable pancreatic cancer, but high-quality …

Simple Summary Recently observed improvement in the treatment of pancreatic ductal
adenocarcinoma (PDAC) has resulted mainly from improved perioperative care and more …

The symposium “New criteria of resectability for pancreatic cancer” was held during the
33nd meeting of the Japanese Society of Hepato‐Biliary‐Pancreatic Surgery (JSHBPS) in …

PURPOSE Previous studies suggest that besides anatomy (A: resectable, borderline
resectable [BR], or locally advanced [LA]) also biologic (B: carbohydrate antigen 19-9 [CA 19 …

Introduction About 25% of patients with localized pancreatic adenocarcinoma have non-
elevated serum carbohydrate antigen (CA) 19-9 levels at baseline, hampering evaluation of …

Background The prognostic and predictive value of carbohydrate antigen 19-9 (CA 19-9) in
locally advanced pancreatic cancer (LAPC) has not yet been defined from prospective …

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy. Despite the
development of multimodality treatments, including surgical resection, radiotherapy, and …

Abstract Background The International Consensus Criteria (ICC)(2017) redefined patients
with borderline resectable pancreatic ductal adenocarcinoma (BR-PDAC) according to …

Background Guidelines suggest that the serum carbohydrate antigen (CA19-9) level should
be used when deciding on neoadjuvant treatment in patients with resectable and borderline …